Evidence map›Paper›PMID 39013884›Full record

ArticleNature communications2024

Antibody Fc-receptor FcεR1γ stabilizes cell surface receptors in group 3 innate lymphoid cells and promotes anti-infection immunity.

Chao Huang, Wenting Zhu, Qing Li, Yuchen Lei, Xi Chen, Shaorui Liu, Dianyu Chen, Lijian Zhong, Feng Gao, Shujie Fu and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Experimental and therapeutic medicine · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Early-life human CD8Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chao Huang *Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China. huangchao@ucas.ac.cn.ORCID 0000-0002-4082-5598
Wenting Zhu *Laboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Qing Li *Key Laboratory of Multi-Cell Systems, Shanghai Key Laboratory of Molecular Andrology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0002-6392-9699
Yuchen Lei *Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
Xi ChenLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Shaorui LiuLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Dianyu ChenLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Lijian ZhongKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
Feng GaoLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Shujie FuLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Danyang HeLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Jinsong LiKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0003-3456-662X
Heping XuLaboratory of Systems Immunology, School of Medicine, Westlake University, Hangzhou, Zhejiang, China. xuheping@westlake.edu.cn.ORCID 0000-0003-2149-7004

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Group 3 innate lymphoid cells (ILC3) are crucial for maintaining mucosal homeostasis and regulating inflammatory diseases, but the molecular mechanisms governing their phenotype and function are not fully understood. Here, we show that ILC3s highly express Fcer1g gene, which encodes the antibody Fc-receptor common gamma chain, FcεR1γ. Genetic perturbation of FcεR1γ leads to the absence of critical cell membrane receptors NKp46 and CD16 in ILC3s. Alanine scanning mutagenesis identifies two residues in FcεR1γ that stabilize its binding partners. FcεR1γ expression in ILC3s is essential for effective protective immunity against bacterial and fungal infections. Mechanistically, FcεR1γ influences the transcriptional state and proinflammatory cytokine production of ILC3s, relying on the CD16-FcεR1γ signaling pathway. In summary, our findings highlight the significance of FcεR1γ as an adapter protein that stabilizes cell membrane partners in ILC3s and promotes anti-infection immunity.

Indexed as

Immunity, InnateLymphocytesMice, Inbred C57BLReceptors, IgEAnimalsHumansMiceMice, KnockoutReceptors, IgGSignal TransductionReceptors, IgEReceptors, IgG

Identifiers

PMID39013884
PMCPMC11252441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.